What is Nucleix?
Nucleix is a specialized liquid biopsy company dedicated to revolutionizing cancer treatment through earlier, more accurate disease detection. By utilizing a sophisticated combination of Next-Generation Sequencing (NGS) and PCR-based epigenetics, the company has developed the EpiCheck platform. This technology provides a non-invasive, highly sensitive method for identifying cancer markers, offering a critical advantage for patients when intervention is most effective.
The company's market position is anchored by its flagship Bladder EpiCheck testing kit, which is currently marketed in Europe for the management of bladder cancer recurrence. Nucleix is actively advancing its pipeline, with the Lung EpiCheck test currently moving toward commercialization. By focusing on high-risk diseases, Nucleix is establishing a robust franchise that integrates seamlessly into existing healthcare systems, providing clinicians with actionable data to improve patient outcomes.
How much funding has Nucleix raised?
Nucleix has raised a total of $85M across 4 funding rounds:
Unspecified
$5M
Unspecified
$3M
Other Financing Round
$55M
Other Financing Round
$22M
Unspecified (2014): $5M with participation from OrbiMed Advisors LLC
Unspecified (2016): $3M led by Aurum and OrbiMed Israel Partners
Other Financing Round (2021): $55M supported by LYFE Capital, OrbiMed, Zohar Zisapel, Aurum Ventures Private, RA Capital Management, MILFAM, OCI Bio Investments, BlackRock, Lilly Asia Ventures, and DSC Investment
Other Financing Round (2022): $22M featuring Sands Capital
Key Investors in Nucleix
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics with deep expertise in life sciences innovation.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare companies, utilizing its internal think tank, TechAtlas, to support scientific and clinical development.
BlackRock
BlackRock is a global investment management firm that provides institutional clients with comprehensive asset management, risk management, and advisory services across diverse sectors including healthcare and life sciences.
What's next for Nucleix?
With the support of its latest capital injection, Nucleix is well-positioned to transition from a clinical-stage innovator to a commercial-scale diagnostic leader. The strategic roadmap focuses on the aggressive expansion of the EpiCheck franchise, specifically targeting the commercial launch of the Lung EpiCheck test. Furthermore, the company is expected to allocate resources toward the development of additional diagnostic assays for high-risk oncological conditions, further diversifying its portfolio.
As the company scales, it will likely prioritize regulatory milestones and clinical validation studies to solidify its presence in international markets. The continued backing from top-tier healthcare investors provides the necessary operational runway to refine its methylation-based technology and enhance its competitive edge in the rapidly evolving liquid biopsy sector.
